

# Christoph Oing

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/276647/publications.pdf>

Version: 2024-02-01

74  
papers

2,343  
citations

279487

23  
h-index

233125

45  
g-index

98  
all docs

98  
docs citations

98  
times ranked

2497  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. <i>Histopathology</i> , 2022, 80, 381-396.	1.6	10
2	Therapy of clinical stage IIA and IIB seminoma: a systematic review. <i>World Journal of Urology</i> , 2022, 40, 2829-2841.	1.2	6
3	The impact of COVID-19 on oncology professionalsâ€™ one year on: lessons learned from the ESMO Resilience Task Force survey series. <i>ESMO Open</i> , 2022, 7, 100374.	2.0	24
4	Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). <i>World Journal of Urology</i> , 2022, 40, 355-361.	1.2	2
5	Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry. <i>World Journal of Urology</i> , 2022, 40, 373.	1.2	3
6	First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment. <i>World Journal of Urology</i> , 2022, , 1.	1.2	1
7	Approaches of stem cell mobilization in a large cohort of metastatic germ cell cancer patients. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	1
8	Chromosome 3p25.3 Gain Is Associated With Cisplatin Resistance and Is an Independent Predictor of Poor Outcome in Male Malignant Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 3077-3087.	0.8	13
9	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 825-832.	0.4	2
10	The detection of isochromosome i(12p) in malignant germ cell tumours and tumours with somatic malignant transformation by the use of quantitative real-time polymerase chain reaction. <i>Histopathology</i> , 2021, 78, 593-606.	1.6	31
11	Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. <i>Urologia Internationalis</i> , 2021, 105, 169-180.	0.6	37
12	Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II â€œ Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. <i>Urologia Internationalis</i> , 2021, 105, 181-191.	0.6	19
13	ESMO20 YO for YO: highlights on metastatic renal cell carcinomaâ€™the CheckMate-9ER trial. <i>ESMO Open</i> , 2021, 6, 100025.	2.0	7
14	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
15	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	1.2	4
16	Late adverse effects and quality of life in survivors of testicular germ cell tumour. <i>Nature Reviews Urology</i> , 2021, 18, 227-245.	1.9	49
17	The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration. <i>ESMO Open</i> , 2021, 6, 100058.	2.0	47
18	Editorial Comment to Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis. <i>International Journal of Urology</i> , 2021, 28, 847-848.	0.5	0

#	ARTICLE	IF	CITATIONS
19	The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 268.	3.5	27
20	The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II. <i>ESMO Open</i> , 2021, 6, 100199.	2.0	19
21	The developmental origin of cancers defines basic principles of cisplatin resistance. <i>Cancer Letters</i> , 2021, 519, 199-210.	3.2	17
22	Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 449-455.	1.2	10
23	Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. <i>Cancers</i> , 2020, 12, 2903.	1.7	20
24	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	1.9	10
25	Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair. <i>Cancers</i> , 2020, 12, 2467.	1.7	11
26	Human chorionic gonadotropin- $\alpha$ -positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3). <i>European Journal of Cancer</i> , 2020, 132, 127-135.	1.3	8
27	Prognostic impact of LDH and HCG levels in marker-positive seminomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 392-392.	0.8	4
28	Semi-ResMass Study: Residual masses after salvage chemotherapy in men with pure seminoma- A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 420-420.	0.8	0
29	Expression of miRNA-371a-3p in seminal plasma and ejaculate is associated with sperm concentration. <i>Andrology</i> , 2019, 7, 469-474.	1.9	31
30	Prognostic factors in metastatic seminomatous germ cell tumours and elevated human chorionic gonadotrophin (HCG): A study of the G3. <i>Annals of Oncology</i> , 2019, 30, v363-v364.	0.6	1
31	The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 809.e19-809.e25.	0.8	10
32	Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines. <i>Disease Markers</i> , 2019, 2019, 1-14.	0.6	13
33	Current pharmacotherapy for testicular germ cell cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 837-850.	0.9	16
34	Epigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations. <i>Andrology</i> , 2019, 7, 487-497.	1.9	22
35	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1412-1423.	0.8	246
36	Awareness of predatory journals and open access among medical oncologists: results of an online survey. <i>ESMO Open</i> , 2019, 4, e000580.	2.0	15

#	ARTICLE	IF	CITATIONS
37	5-Azacididine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 21.	1.8	49
38	TP53 and Prognosis in mCRPC Survival: Biology or Coincidence?. <i>Clinical Cancer Research</i> , 2019, 25, 1699-1701.	3.2	4
39	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	1.2	25
40	Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. <i>Scientific Reports</i> , 2018, 8, 3947.	1.6	54
41	Therapeutic approaches for refractory germ cell cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 389-397.	1.1	33
42	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. <i>Cancer Letters</i> , 2018, 423, 60-70.	3.2	31
43	Intermediate prognosis in metastatic germ cell tumors (IPCCT): Outcome and prognostic stratification. <i>Annals of Oncology</i> , 2018, 29, viii325.	0.6	0
44	Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry. <i>Journal of Clinical Oncology</i> , 2018, 36, 3381-3387.	0.8	49
45	Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer. <i>Current Opinion in Urology</i> , 2018, 28, 479-484.	0.9	5
46	Palliative treatment of germ cell cancer. <i>Cancer Treatment Reviews</i> , 2018, 71, 102-107.	3.4	19
47	EP-1618: Monoubiquitinated histone H2B as a potential target in treatment resistant germ cell tumors. <i>Radiotherapy and Oncology</i> , 2018, 127, S871.	0.3	3
48	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, 1658-1686.	0.6	228
49	The Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell Tumors. <i>Oncology Research and Treatment</i> , 2018, 41, 365-369.	0.8	16
50	Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. <i>Annals of Oncology</i> , 2017, 28, 576-582.	0.6	20
51	Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care. <i>Oncology Research and Treatment</i> , 2017, 40, 609-615.	0.8	1
52	Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1319-1325.	1.2	26
53	Platinum-refractory germ cell tumors: an update on current treatment options and developments. <i>World Journal of Urology</i> , 2017, 35, 1167-1175.	1.2	25
54	Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours. <i>European Urology</i> , 2017, 71, 213-220.	0.9	161

#	ARTICLE	IF	CITATIONS
55	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.. Journal of Clinical Oncology, 2017, 35, 4521-4521.	0.8	11
56	Ongoing Clinical Trials in Testicular Cancer: The TIGER Trial. Oncology Research and Treatment, 2016, 39, 553-556.	0.8	14
57	Ongoing Clinical Trials in Prostate Cancer: The STAMPEDE Trial. Oncology Research and Treatment, 2016, 39, 464-467.	0.8	1
58	Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1979-1994.	1.2	10
59	Investigational targeted therapies for the treatment of testicular germ cell tumors. Expert Opinion on Investigational Drugs, 2016, 25, 1033-1043.	1.9	25
60	Symptom burden in long-term germ cell tumor survivors. Supportive Care in Cancer, 2016, 24, 2243-2250.	1.0	18
61	Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments. Expert Opinion on Pharmacotherapy, 2016, 17, 545-560.	0.9	13
62	Anxiety and depression in long-term testicular germ cell tumor survivors. General Hospital Psychiatry, 2016, 38, 21-25.	1.2	41
63	Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyondâ€”A Comprehensive Review of the Current Literature. Journal of Urology, 2016, 195, 254-263.	0.2	99
64	Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Research, 2015, 43, 3154-3166.	6.5	105
65	First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database. Journal of Cancer Research and Clinical Oncology, 2015, 141, 923-931.	1.2	7
66	Hodentumoren. , 2015, , 1-13.		0
67	Nodal, pulmonary and pleural gliomatosis in a 42â€”year-oldâ€”male with nonâ€”seminomatous testicular germ cell cancer. Histopathology, 2014, 65, 142-143.	1.6	2
68	First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). Journal of Cancer Research and Clinical Oncology, 2014, 140, 1211-20.	1.2	11
69	Molecular profiling of testicular cancer.. Journal of Clinical Oncology, 2014, 32, 4515-4515.	0.8	0
70	Bone metastases in germ cell tumors: Results from an international data base.. Journal of Clinical Oncology, 2014, 32, 4559-4559.	0.8	0
71	Bone metastases in germ cell tumor patients. Journal of Cancer Research and Clinical Oncology, 2012, 138, 947-952.	1.2	28
72	Bone metastases in patients with relapsed/refractory germ cell tumors (GCT) undergoing first salvage chemotherapy: A retrospective analysis of a large international database.. Journal of Clinical Oncology, 2012, 30, 4597-4597.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. Clinical Epigenetics, 2011, 2, 419-423.	1.8	21
74	Abstract 4815: Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia. , 2011, , .		0